The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
First-in-human, safety, pharmacodynamic (PD) and pharmacokinetic (PK) trial of a first-in-class dual RAF/MEK inhibitor, RO5126766, in patients with advanced or metastatic solid tumors.
S. O. Dolly
No relevant relationships to disclose
J. Albanell
Consultant or Advisory Role - Roche
F. Kraeber-Bodere
Consultant or Advisory Role - Roche
Honoraria - Roche
U. Banerji
No relevant relationships to disclose
R. Bahleda
No relevant relationships to disclose
M. Martinez Garcia
No relevant relationships to disclose
Z. X. Xu
Employment or Leadership Position - Roche
Stock Ownership - Roche
E. Guarin
Employment or Leadership Position - Roche
J. Tessier
Employment or Leadership Position - Roche
E. Shochat
Employment or Leadership Position - Roche
J. Deutsch
Employment or Leadership Position - Roche
Stock Ownership - Roche
S. Blotner
Employment or Leadership Position - Roche
V. Meresse
Employment or Leadership Position - Roche
J. Soria
Honoraria - Roche